<DOC>
	<DOCNO>NCT00716092</DOCNO>
	<brief_summary>The objective study investigate effect BI 1356 24-h glucose control various pharmacodynamic parameter type 2 diabetic patient inadequate glycaemic control .</brief_summary>
	<brief_title>The Effect Linagliptin ( BI 1356 ) 24h-glucose Control Various Biomarkers Type 2 Diabetic Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Inclusion criterion : Male female patient diagnosis type 2 diabetes mellitus previously treat one drug Glycosylated haemoglobin A1 ( HbA1c ) 6.5 10.0 % Start Runin Exclusion criterion : Myocardial infarction , stroke transient ischemic attack `` TIA '' within 6 month prior inform consent Impaired hepatic function Renal insufficiency creatinine clearance &lt; 50 mL/min Treatment rosiglitazone , pioglitazone , glucagon like peptide 1 ( GLP1 ) analogue , insulin , dipeptidyl peptidase 4 ( DPP4 ) inhibitor antiobesity drug 3 month prior inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>